Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
Becton Dickinson gains amid reports it's evaluating separating life sciences unit
Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life sciences segment.
BD to separate Biosciences and Diagnostic Solutions business
The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to further fund growth.
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business. The company has been restructuring its business portfolio in recent years,
Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
MassDevice2d
Activist investors reportedly push BD to sell Life Sciences biz
The Financial Times reports today that an activist investor wants BD (NYSE:BDX) to sell off its Life Sciences business unit.
FierceBiotech13d
Masimo lands new CEO from BD's patient monitoring division
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
Revolutionizing Cervical Cancer Prevention: New Guidelines and Diagnostic Test Offer Personalized Care
ASCCP and NCI Publish Guidance in the Journal of Lower Genital Tract Disease; BD Onclarity HPV Assay Identifies Risk by HPV Type for Tailored Management CLARKSBURG, MARYLAND / ACCESS Newswire / ...
Becton Dickinson to separate biosciences, diagnostic solutions business
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...